Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries

Autor: Susanne Qvitzau, Andrew J. K. Östör, Alan Reynolds, Rose-Marie Lindkvist, Mats Ekelund, Per Larsson, Robert J. Moots, Pentti Järvinen, Anne G. R. Loft, Danuta Kielar

Publikováno v: Moots, R J, Ostor, A J K, Loft, A G R, Järvinen, P, Larsson, P, Ekelund, M, Reynolds, A, Kielar, D, Lindkvist, R-M & Qvitzau, S 2012, ' Reduction of direct and indirect costs in patients with AS receiving etanercept : results from an open-label 36-week extension of the ASCEND study in four European countries ', Rheumatology, vol. 51, no. 2, pp. 393-6 . https://doi.org/10.1093/rheumatology/ker404

OBJECTIVE: To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).METHODS: A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1bf42659488942e087c8e5568d93c17
https://doi.org/10.1093/rheumatology/ker404